RRx-001, an experimental systemically nontoxic epi-immunotherapeutic agent, which potentiates the resensitization of resistant tumor cells to formerly effective therapies, is less than active investigation in a number of clinical tests that derive from sequential or concomitant rechallenge to resistant 1st- or second-line regimens. a technique to episensitize tumors (i.e. opposite level of resistance by epigenetic… Continue reading RRx-001, an experimental systemically nontoxic epi-immunotherapeutic agent, which potentiates the resensitization